Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Down 88.7% in December

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totaling 11,203 shares, a drop of 88.7% from the December 15th total of 98,734 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 48,099 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily volume of 48,099 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company’s shares are sold short.

Fresenius SE & Co. Stock Performance

Shares of FSNUY stock traded up $0.23 during trading hours on Wednesday, reaching $15.13. The company’s stock had a trading volume of 79,898 shares, compared to its average volume of 49,738. The firm’s fifty day simple moving average is $14.17 and its 200 day simple moving average is $13.88. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 0.99. Fresenius SE & Co. has a one year low of $9.07 and a one year high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its earnings results on Wednesday, November 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.02. The company had revenue of $6.29 billion for the quarter, compared to analysts’ expectations of $6.38 billion. Fresenius SE & Co. had a net margin of 5.26% and a return on equity of 9.72%. On average, research analysts expect that Fresenius SE & Co. will post 0.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research note on Monday, October 27th. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Monday, December 15th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.